Ruxolitinib compared with best available therapy for essential thrombocythaemia patients resistant or intolerant to hydroxycarbamide in majic: an investigator lead randomized trial - Harrison, C; Mead, A; Panchal, A; Fox, S; Yap, C; Houlton, A; Aliman, S; Wood, M; Chen, F; Coppell, J; Panoskaltsis, N; Scherber, R; et al. (Haematologica, 2016)